BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892-913. [PMID: 30194708 DOI: 10.1111/apt.14952] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Brauner C, Joveleviths D, Álvares-da-silva MR, Marroni N, Bona S, Schemitt E, Nardi R. Exposure to organic solvents and hepatotoxicity. Journal of Environmental Science and Health, Part A 2020;55:1173-8. [DOI: 10.1080/10934529.2020.1779532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Reuben A. Drug-Induced Liver Injury in Liver Transplant Recipients: Informed Insights and Sage Advice From Andalusia. Liver Transpl 2020;26:1088-9. [PMID: 32717122 DOI: 10.1002/lt.25853] [Reference Citation Analysis]
3 Allard J, Le Guillou D, Begriche K, Fromenty B. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. Adv Pharmacol 2019;85:75-107. [PMID: 31307592 DOI: 10.1016/bs.apha.2019.01.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
4 Raschi E, De Ponti F. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Front Pharmacol 2019;10:1235. [PMID: 31708776 DOI: 10.3389/fphar.2019.01235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
5 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019;7:E27. [PMID: 30823570 DOI: 10.3390/diseases7010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
6 Bessone F, Hernandez N, Tagle M, Arrese M, Parana R, Méndez-Sánchez N, Ridruejo E, Mendizabal M, Dagher L, Contreras F, Fassio E, Pesoa M, Brahm J, Silva M. Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Ann Hepatol 2021;24:100321. [PMID: 33609753 DOI: 10.1016/j.aohep.2021.100321] [Reference Citation Analysis]
7 LaBranche TP, Kopec AK, Mantena SR, Hollingshead BD, Harrington AW, Stewart ZS, Zhan Y, Hayes KD, Whiteley LO, Burdick AD, Davis JW 2nd. Zucker Lean Rats With Hepatic Steatosis Recapitulate Asymptomatic Metabolic Syndrome and Exhibit Greater Sensitivity to Drug-Induced Liver Injury Compared With Standard Nonclinical Sprague-Dawley Rat Model. Toxicol Pathol 2020;48:994-1007. [PMID: 33252024 DOI: 10.1177/0192623320968716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Saitoh K, Yoshimura T, Sun L, Yang M, Wang Y, Taniyama S, Hara K, Murayama F, Nikawa T, Tachibana K, Hirasaka K. Effect of dietary fish oil on enhanced inflammation and disturbed lipophagy in white adipose tissue caused by a high fat diet. Fish Sci 2020;86:187-96. [DOI: 10.1007/s12562-019-01374-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Zhao Z, Peng W, Zhou J, Zhou Y, Liu T, Bai H, Wu Q, Song J, Wu L, Song X, Ying B. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population. Infection, Genetics and Evolution 2019;75:103970. [DOI: 10.1016/j.meegid.2019.103970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Isaacson RH, Beier JI, Khoo NK, Freeman BA, Freyberg Z, Arteel GE. Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane. J Nutr Biochem 2020;81:108399. [PMID: 32388251 DOI: 10.1016/j.jnutbio.2020.108399] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology 2019;13:849-66. [DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
12 Todorović Vukotić N, Đorđević J, Pejić S, Đorđević N, Pajović SB. Antidepressants- and antipsychotics-induced hepatotoxicity. Arch Toxicol 2021;95:767-89. [PMID: 33398419 DOI: 10.1007/s00204-020-02963-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry SM, Hamid S, Tan SS, Philips CA, George J, Jafri W, Sarin SK; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int 2021;15:258-82. [PMID: 33641080 DOI: 10.1007/s12072-021-10144-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
14 Caballano-infantes E, García-garcía A, Lopez-gomez C, Cueto A, Robles-diaz M, Ortega-alonso A, Martín-reyes F, Alvarez-alvarez I, Arranz-salas I, Ruiz-cabello F, Lucena IM, García-fuentes E, Andrade RJ, García-cortes M. Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. Biomedicines 2022;10:55. [DOI: 10.3390/biomedicines10010055] [Reference Citation Analysis]
15 Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol 2021;116:878-98. [PMID: 33929376 DOI: 10.14309/ajg.0000000000001259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ferron PJ, Gicquel T, Mégarbane B, Clément B, Fromenty B. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? Biochimie 2020;179:266-74. [PMID: 32891697 DOI: 10.1016/j.biochi.2020.08.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73:807-816. [PMID: 32437830 DOI: 10.1016/j.jhep.2020.05.002] [Cited by in Crossref: 158] [Cited by in F6Publishing: 161] [Article Influence: 79.0] [Reference Citation Analysis]
18 Huang R, Zhu L, Wang J, Xue L, Liu L, Yan X, Huang S, Li Y, Yan X, Zhang B, Xu T, Li C, Ji F, Ming F, Zhao Y, Cheng J, Wang Y, Zhao H, Hong S, Chen K, Zhao XA, Zou L, Sang D, Shao H, Guan X, Chen X, Chen Y, Wei J, Zhu C, Wu C. Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. Hepatol Commun 2020. [PMID: 32838108 DOI: 10.1002/hep4.1592] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
19 Gao A, Jiang J, Xie F, Chen L. Bnip3 in mitophagy: Novel insights and potential therapeutic target for diseases of secondary mitochondrial dysfunction. Clin Chim Acta 2020;506:72-83. [PMID: 32092316 DOI: 10.1016/j.cca.2020.02.024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
20 Cardenas V, Mankuzhy N, Mody R, McCaffery H, Fontana RJ, DiPaola F. Incidence and Sequelae of Liver Injury Among Children Treated for Solid Tumors: Analysis of a Large Single-Center Prospective Cohort. J Pediatr Gastroenterol Nutr 2020;71:197-202. [PMID: 32404749 DOI: 10.1097/MPG.0000000000002767] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T. Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. Journal of Gastroenterology and Hepatology 2020;35:1042-8. [DOI: 10.1111/jgh.14889] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99-128. [PMID: 30343320 DOI: 10.1007/s00018-018-2947-0] [Cited by in Crossref: 109] [Cited by in F6Publishing: 118] [Article Influence: 27.3] [Reference Citation Analysis]
24 Cho MK, Seo MJ, Juvekar V, Jo JH, Kim W, Choi KS, Kim HM. Screening of Drug-Induced Steatosis and Phospholipidosis Using Lipid Droplet-Selective Two-Photon Probes. Anal Chem 2020;92:11223-31. [DOI: 10.1021/acs.analchem.0c01728] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
25 Bartoli A, Gitto S, Sighinolfi P, Cursaro C, Andreone P. Primary biliary cholangitis associated with SARS-CoV-2 infection. J Hepatol 2021;74:1245-6. [PMID: 33610679 DOI: 10.1016/j.jhep.2021.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
26 Fernandez-Checa JC, Bagnaninchi P, Ye H, Sancho-Bru P, Falcon-Perez JM, Royo F, Garcia-Ruiz C, Konu O, Miranda J, Lunov O, Dejneka A, Elfick A, McDonald A, Sullivan GJ, Aithal G, Lucena MI, Andrade RJ, Fromenty B, Krannendonk M, Cubero FJ, Nelson LJ. ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET]. J Hepatol 2021:S0168-8278(21)00441-4. [PMID: 34171436 DOI: 10.1016/j.jhep.2021.06.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 You D, Lyn-Cook LE, Gatti DM, Bell N, Mayeux PR, James LP, Mattes WB, Larson GJ, Harrill AH. Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice. Toxicol Sci 2020;175:220-35. [PMID: 32170957 DOI: 10.1093/toxsci/kfaa037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Alfani R, Vassallo E, De Anseris AG, Nazzaro L, D'Acunzo I, Porfito C, Mandato C, Vajro P. Pediatric Fatty Liver and Obesity: Not Always Justa Matter of Non-Alcoholic Fatty Liver Disease. Children (Basel) 2018;5:E169. [PMID: 30551665 DOI: 10.3390/children5120169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Cataldi M, Citro V, Resnati C, Manco F, Tarantino G. New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants. Adv Ther 2021;38:2094-113. [PMID: 33761100 DOI: 10.1007/s12325-021-01669-y] [Reference Citation Analysis]
30 Jain S, Norinder U, Escher SE, Zdrazil B. Combining In Vivo Data with In Silico Predictions for Modeling Hepatic Steatosis by Using Stratified Bagging and Conformal Prediction. Chem Res Toxicol 2021;34:656-68. [PMID: 33347274 DOI: 10.1021/acs.chemrestox.0c00511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Aranha MLG, Garcia MS, de Carvalho Cavalcante DN, Silva APG, Fontes MK, Gusso-Choueri PK, Choueri RB, Perobelli JE. Biochemical and histopathological responses in peripubertal male rats exposed to agrochemicals isolated or in combination: A multivariate data analysis study. Toxicology 2021;447:152636. [PMID: 33217513 DOI: 10.1016/j.tox.2020.152636] [Reference Citation Analysis]
32 Zeng H, Lin Y, Gong J, Lin S, Gao J, Li C, Feng Z, Zhang H, Zhang J, Li Y, Yu C. CYP3A suppression during diet-induced nonalcoholic fatty liver disease is independent of PXR regulation. Chem Biol Interact 2019;308:185-93. [PMID: 31132328 DOI: 10.1016/j.cbi.2019.05.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
33 Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf 2019;42:365-87. [PMID: 30343418 DOI: 10.1007/s40264-018-0743-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
34 Fromenty B. Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis. Liver Research 2019;3:157-69. [DOI: 10.1016/j.livres.2019.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Rahban M, Stanek A, Hooshmand A, Khamineh Y, Ahi S, Kazim SN, Ahmad F, Muronetz V, Samy Abousenna M, Zolghadri S, Saboury AA. Infection of Human Cells by SARS-CoV-2 and Molecular Overview of Gastrointestinal, Neurological, and Hepatic Problems in COVID-19 Patients. J Clin Med 2021;10:4802. [PMID: 34768321 DOI: 10.3390/jcm10214802] [Reference Citation Analysis]
36 Lee HW, Lee IJ, Lee SJ, Kim YR, Kim HM. Highly Sensitive Two-Photon Lipid Droplet Tracker for In Vivo Screening of Drug Induced Liver Injury. ACS Sens 2022. [PMID: 35385270 DOI: 10.1021/acssensors.1c02679] [Reference Citation Analysis]
37 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]